International legal business DWF has advised the anti-cancer drug manufacturer ADC Biotechnology on securing a multi-million pound investment from private equity house Maven Capital Partners. The £8m will build a dedicated pharmaceutical facility, creating 50 scientific jobs.

International legal business DWF has advised the anti-cancer drug manufacturer ADC Biotechnology on securing a multi-million pound investment from private equity house Maven Capital Partners. The £8m will build a dedicated pharmaceutical facility, creating 50 scientific jobs.

ADC Biotechnology operates in the highest growth sector within oncology therapeutics and has developed a unique patented lock-release technology for the development and manufacture of antibody drug conjugates (ADC) group of cancer therapies which are designed to specifically target and kill tumour cells.

ADCs are the next generation of highly effective anti-cancer drugs, which result in reduced side effects compared to conventional chemotherapy and could provide treatment for a wide range of cancers.

The deal sees ADC complete its strategic move into clinical and commercial ADC manufacturing, and convert its already strong consumer base, which is currently focused on manufacturing for R&D applications and includes large pharmaceutical companies, to higher value clinical development work.

Frank Shephard, National Head of Corporate at DWF, advised on the deal with support from Katy Phillips, corporate associate.

Frank Shephard said: "We are pleased to have acted on this transaction which will enable ADC progress its next strategic phase of growth, and which reflects DWF's expertise and continuous growth in sector capabilities."